zh-twzhen
zh-twzhen

NEWS

合一生技股份有限公司 / 2021 / Oneness Biotech Co., LTD. receives “Prior Authorisation for Import of Traditional Medicines” from Macau on Fespixon cream (Research code: ON101)

Oneness Biotech Co., LTD. receives “Prior Authorisation for Import of Traditional Medicines” from Macau on Fespixon cream (Research code: ON101)

2021-12-16

Published Date:2021-12-16

Original Link:https://www.onenessbio.com/en/news_detail129_1.htm

No 1 Date of announcement 2021/12/16 Time of announcement 17:19:51
Subject Oneness Biotech Co., LTD. receives “Prior Authorisation for Import of Traditional Medicines” from Macau on Fespixon cream (Research code: ON101)
To which item it meets paragraph 53 Date of events 2021/12/16
Statement
    
    
1.Date of occurrence of the event:2021/12/16
2.Company name:ONENESS BIOTECH CO., LTD.
3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:The Company has been informed by Authorized Agent that Macau issued ”Prior Authorisation for Import of Traditional Medicines” on Fespixon cream (Research code: ON101).
6.Countermeasures:None
7.Any other matters that need to be specified:
(1)Fespixon cream can be exported to Macau after receiving ”Prior Authorisation for Import of Traditional Medicines” from Macau Health Bureau.
(2)The exclusive commercialization right of Fespixon cream (Research code: ON101), a new drug for diabetic foot ulcer, for mainland China, Hong Kong and Macau has been licensed to Microbio (Shanghai) Co., Ltd.